Growth Metrics

Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2016 - 2025)

Vanda Pharmaceuticals' Cash from Financing Activities history spans 14 years, with the latest figure at -$640000.0 for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 312.9% to -$640000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.9 million, a 1774.84% decrease, with the full-year FY2025 number at -$2.9 million, down 1774.84% from a year prior.
  • Cash from Financing Activities hit -$640000.0 in Q4 2025 for Vanda Pharmaceuticals, down from -$517000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for VNDA hit a ceiling of $1.8 million in Q1 2021 and a floor of -$1.3 million in Q1 2025.
  • Historically, Cash from Financing Activities has averaged $101916.7 across 4 years, with a median of $64500.0 in 2022.
  • Biggest five-year swings in Cash from Financing Activities: surged 286.01% in 2021 and later crashed 312.9% in 2025.
  • Tracing VNDA's Cash from Financing Activities over 4 years: stood at $1.0 million in 2021, then crashed by 41.88% to $605000.0 in 2022, then crashed by 125.62% to -$155000.0 in 2024, then crashed by 312.9% to -$640000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for VNDA at -$640000.0 in Q4 2025, -$517000.0 in Q3 2025, and -$425000.0 in Q2 2025.